Assessing live microbial therapeutic transmission
The development of fecal microbiota transplantation and defined live biotherapeutic products for the treatment of human disease has been an empirically driven process yielding a notable success of approved drugs for the treatment of recurrent Clostridioides difficile infection. Assessing the potenti...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Gut Microbes |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19490976.2024.2447836 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841561247635472384 |
|---|---|
| author | Jeremiah J. Faith |
| author_facet | Jeremiah J. Faith |
| author_sort | Jeremiah J. Faith |
| collection | DOAJ |
| description | The development of fecal microbiota transplantation and defined live biotherapeutic products for the treatment of human disease has been an empirically driven process yielding a notable success of approved drugs for the treatment of recurrent Clostridioides difficile infection. Assessing the potential of this therapeutic modality in other indications with mixed clinical results would benefit from consistent quantitative frameworks to characterize drug potency and composition and to assess the impact of dose and composition on the frequency and duration of strain engraftment. Monitoring these drug properties and engraftment outcomes would help identify minimally sufficient sets of microbial strains to treat disease and provide insights into the intersection between microbial function and host physiology. Broad and correct usage of strain detection methods is essential to this advancement. This article describes strain detection approaches, where they are best applied, what data they require, and clinical trial designs that are best suited to their application. |
| format | Article |
| id | doaj-art-3903bf401f334e2d93cb2b5977b078a2 |
| institution | Kabale University |
| issn | 1949-0976 1949-0984 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Gut Microbes |
| spelling | doaj-art-3903bf401f334e2d93cb2b5977b078a22025-01-03T04:00:53ZengTaylor & Francis GroupGut Microbes1949-09761949-09842025-12-0117110.1080/19490976.2024.2447836Assessing live microbial therapeutic transmissionJeremiah J. Faith0Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USAThe development of fecal microbiota transplantation and defined live biotherapeutic products for the treatment of human disease has been an empirically driven process yielding a notable success of approved drugs for the treatment of recurrent Clostridioides difficile infection. Assessing the potential of this therapeutic modality in other indications with mixed clinical results would benefit from consistent quantitative frameworks to characterize drug potency and composition and to assess the impact of dose and composition on the frequency and duration of strain engraftment. Monitoring these drug properties and engraftment outcomes would help identify minimally sufficient sets of microbial strains to treat disease and provide insights into the intersection between microbial function and host physiology. Broad and correct usage of strain detection methods is essential to this advancement. This article describes strain detection approaches, where they are best applied, what data they require, and clinical trial designs that are best suited to their application.https://www.tandfonline.com/doi/10.1080/19490976.2024.2447836Microbiomestrain trackingmicrobial therapeuticsfecal microbiota transplantationlive biotherapeutic product |
| spellingShingle | Jeremiah J. Faith Assessing live microbial therapeutic transmission Gut Microbes Microbiome strain tracking microbial therapeutics fecal microbiota transplantation live biotherapeutic product |
| title | Assessing live microbial therapeutic transmission |
| title_full | Assessing live microbial therapeutic transmission |
| title_fullStr | Assessing live microbial therapeutic transmission |
| title_full_unstemmed | Assessing live microbial therapeutic transmission |
| title_short | Assessing live microbial therapeutic transmission |
| title_sort | assessing live microbial therapeutic transmission |
| topic | Microbiome strain tracking microbial therapeutics fecal microbiota transplantation live biotherapeutic product |
| url | https://www.tandfonline.com/doi/10.1080/19490976.2024.2447836 |
| work_keys_str_mv | AT jeremiahjfaith assessinglivemicrobialtherapeutictransmission |